Spectral Diagnostics Inc. (OTCMKTS:EDTXF) Short Interest Update

Spectral Diagnostics Inc. (OTCMKTS:EDTXF) was the target of a large drop in short interest in September. As of September 15th, there was short interest totaling 7,906 shares, a drop of 39.6% from the August 31st total of 13,085 shares. Based on an average trading volume of 14,380 shares, the short-interest ratio is presently 0.5 days. Approximately 0.0% of the shares of the company are short sold.

Spectral Diagnostics Stock Performance

Shares of EDTXF opened at $0.83 on Wednesday. The company has a 50-day simple moving average of $0.94 and a 200-day simple moving average of $0.97. The firm has a market capitalization of $244.55 million, a P/E ratio of -8.30 and a beta of 0.16. Spectral Diagnostics has a 52 week low of $0.65 and a 52 week high of $1.15.

Spectral Diagnostics Company Profile

Spectral Diagnostics, now known as Spectral Medical Inc, is a Canadian medical-device and biotechnology company focused on products for the diagnosis and treatment of sepsis and septic shock. The company’s work centers on identifying endotoxemia, a condition in which bacterial endotoxins enter the bloodstream and can contribute to severe systemic inflammation.

Spectral’s primary diagnostic product is the Endotoxin Activity Assay (EAA), a blood test designed to measure a patient’s endotoxin activity and help identify individuals who may be at increased risk of developing severe sepsis.